Psilocybin for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 8 registered trials.

Why this status

  1. 13 Dec 2018: Trial registered, NCT03775200
  2. 1 Mar 2019: Trial started, NCT03775200
  3. 16 Jun 2020: Trial registered, NCT04433858
  4. 1 Mar 2021: Trial started, NCT04433858
  5. 21 Jun 2021: Trial started, NCT04959253
  6. 13 Jul 2021: Trial registered, NCT04959253
  7. 31 Aug 2021: Trial registered, NCT05029466
  8. 19 Nov 2021: Trial started, NCT05029466
  9. 2 Feb 2022: Trial registered, NCT05220410
  10. 28 Mar 2022: Trial started, NCT05220410
  11. 30 Jan 2024: Trial registered, NCT06230757
  12. 8 Jul 2024: Trial started, NCT06230757
  13. 7 Oct 2025: Trial registered, NCT07210112
  14. 30 Jun 2026: Trial started, NCT07210112

The trials

NCT03775200: The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

State
Completed
Phase
Phase 2
People
233 taking part
Started
1 Mar 2019
Primary completion
30 Jul 2021
Arms
Low dose, Medium dose, High dose
Results
Posted on the registry
  1. 13 Dec 2018: Trial registered
  2. 1 Mar 2019: Trial started
  3. 27 Sep 2021: Trial completed
  4. 24 Apr 2023: Trial results posted

NCT04433858: An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

State
State not given
Phase
Phase 2
People
27 taking part
Started
1 Mar 2021
Primary completion
1 Jun 2025
Arms
Psilocybin
Results
None posted
  1. 16 Jun 2020: Trial registered
  2. 1 Mar 2021: Trial started

NCT04959253: Psilocybin in Depression Resistant to Standard Treatments

State
Completed
Phase
Phase 2
People
60 taking part
Started
21 Jun 2021
Primary completion
18 Dec 2024
Arms
Psilocybin 25mg PO
Results
None posted
  1. 21 Jun 2021: Trial started
  2. 13 Jul 2021: Trial registered
  3. 18 Dec 2024: Trial completed

NCT05029466: Psilocybin for Treatment-Resistant Depression

State
Completed
Phase
Phase 2
People
30 taking part
Started
19 Nov 2021
Primary completion
22 Jul 2023
Arms
Immediate treatment, Delayed treatment
Results
None posted
  1. 31 Aug 2021: Trial registered
  2. 19 Nov 2021: Trial started
  3. 22 Jul 2023: Trial completed

NCT05220410: The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

State
Completed
Phase
Phase 2
People
20 taking part
Started
28 Mar 2022
Primary completion
12 May 2025
Arms
Psilocybin
Results
None posted
  1. 2 Feb 2022: Trial registered
  2. 28 Mar 2022: Trial started
  3. 12 May 2025: Trial completed

NCT05381974: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

State
Withdrawn before it started
Phase
Phase 2
People
0 taking part
Started
15 Sep 2022
Primary completion
1 Jun 2023
Arms
Psilocybin
Results
None posted
  1. 19 May 2022: Trial registered
  2. 15 Sep 2022: Trial started
  3. 24 Jan 2024: Trial withdrawn

NCT06230757: Psilocybin for Treatment-Resistant Depression

State
Completed
Phase
Phase 2
People
20 taking part
Started
8 Jul 2024
Primary completion
8 May 2026
Arms
Psilocybin
Results
None posted
  1. 30 Jan 2024: Trial registered
  2. 8 Jul 2024: Trial started
  3. 8 May 2026: Trial completed

NCT07210112: Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

State
Under way
Phase
Phase 2
People
112 planned
Started
30 Jun 2026
Primary completion
31 Dec 2029
Arms
Group 3
Results
None posted
  1. 7 Oct 2025: Trial registered
  2. 30 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as High Dose Psilocybin, Low Dose Psilocybin, Medium Dose Psilocybin, Psilocybin (0.25mg/kg), Psilocybin (Usona Institute), Psilocybin (drug), Psilocybin 100 mcg/kg, Psilocybin 25 mg, Psilocybin 25 mg per os, Psilocybin 25mg, Psilocybin assisted therapy, Psilocybin first, Psilocybin plus Visual Healing Set and Setting, Psilocybin therapy, psilocybin 25 mg sod.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.